Sulfinpyrazone
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
Clinical data | |
---|---|
Trade names | Anturan, Anturane, Apo-sulfinpyrazone |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682339 |
Routes of administration | By mouth intravenous |
ATC code | |
Pharmacokinetic data | |
Protein binding | 98–99% |
Metabolism | liver |
Excretion | kidney |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.325 |
Chemical and physical data | |
Formula | C23H20N2O3S |
Molar mass | 404.48 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Contraindications
Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1]
Research
Trial have found that, Sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from a myocardial infarction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their heart attack. [2]
References
- Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.
- "Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction". New England Journal of Medicine. 302 (5): 250–256. 1980-01-31. doi:10.1056/NEJM198001313020502. ISSN 0028-4793. PMID 6985706.